Smartest Doc
The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences
Diabetes, Obesity and Metabolism, 08/02/2012
Home PD – The largest benefits in efficacy, hypoglycaemia incidence, treatment satisfaction and quality of life have occurred when patients receive an all–analogue meal–time plus basal regimen as compared with an all–human insulin regimen. No new safety issues have been identified with the marketed rapid–acting analogues, and their insulin–like growth factor 1receptor affinity and mitogenic activity are comparable to human insulin.